SEARCH

SEARCH BY CITATION

References

  • 1
    Coulter, DA, Sombati, S, DeLorenzo, RJ. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia 1995;36(suppl 3):S40.
  • 2
    Severt, L, Coulter, DA, Sombati, S, DeLorenzo, RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons. Epilepsia 1995;36(suppl 4):S38.
  • 3
    Gibbs, JW, Sombati, S, DeLorenzo, RJ, Coulter, DA. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000;41(Suppl 1)S106.
  • 4
    Pruss, RM, Akeson, RL, Racke, MM, Wilburn, JL. Agonist-activated cobalt uptake identifies divalent cation-permeable kainate receptors on neurons and glial cells. Neuron 1991;7:50918.
  • 5
    Parks, TN, Artman, LD, Alasti, N, Nemeth, EF. Modulation of N-methyl-d-aspartate receptor-mediated increases in cytosolic calcium in cultured rat cerebellar granule cells. Brain Res 1991;552:1322.
  • 6
    Chapman, AG, Smith, SE, Meldrum, BS. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice. Epilepsy Res 1991;9:926.
  • 7
    Durmiller, N, Graggs, M, Meldrum, BS. The effect of the non-NMDA receptor antagonist D-CPPene on the development of amygdala kindling and on amygdala-kindled seizures. Epilepsy Res 1994;17:16774.
  • 8
    Rogawski, MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993;14:32531.
  • 9
    Smith, S, Durmuller, N, Meldrum, BS. The non-N-methyl-d-aspartate receptor antagonists, GYKI 52466 and NBQX are anti-convulsants in two animal models of reflex epilepsy. Eur J Pharmacol 1991;201:17983.
  • 10
    Yamaguchi, S-I, Donevan, SD, Rogawski, MA. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models. Epilepsy Res 1993;15:17984.
  • 11
    Sharief, M, Viteri, C, Ben-Menachem, E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory epilepsy. Epilepsy Res 1996;25:21724.
  • 12
    Tassinari, CA, Michelucci, R, Chauvel, P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:7638.
  • 13
    Ben-Menachem, E, Henriksen, O, Dam, M, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:53943.
  • 14
    Faught, E, Wilder, BJ, Ramsay, RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:168490.
  • 15
    Privitera, M, Fincham, R, Penry, J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:167883.
  • 16
    Sachdeo, RC, Glauser, TA, Ritter, F, Reife, R, Lim, P, Pledger, G, Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:188287.
  • 17
    Elterman, RD, Glauser, TA, Wyllie, E, Reife, R, Wu, S-C, Pledger, G, Topiramate UP Study Group. A double-blind randomized trial of topiramate as adjunctive therapy for partial onset seizures in children. Neurology 1999;52:133844.
  • 18
    Biton, V, Montouris, GC, Ritter, F, Riviello, JJ, Reife, R, Lim, P, Pledger, G, Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:133037.
  • 19
    Hollmann, M, Heinemann, S. Cloned glutamate receptors. Annu Rev Neurosci 1994;17:31108.